Male Urogenital Diseases

160 trials 69 recruiting

Filter these 160 trials by phase, country and sponsor.

Open in Search →

First in human study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with… Recruiting

2024-512894-29-00 Prostate Cancer 7 2019-11-15
Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy Recruiting

2024-517854-91-00 Metastatic or high-risk recurrent prostate cancer manag 5 2019-08-05
A Phase III trial of acetylsalicylic acid and atorvastatin in patients with castrate-resistant prostate cancer (PEACE 4) Recruiting

2023-508072-11-00 Castration-resistant prostate cancer 5 2019-06-26
The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in treatment naive metastatic pros… Recruiting

2024-519516-14-01 Metastatic prostate cancer, Prostate cancer 4 2019-04-15
Intravesical instillation therapy with bacillus Calmette-Guérin (BCG) and sequential BCG and electromotive mitomycin-C (EMDA-MMC) in patient… Recruiting

2024-516320-33-00 Bladder cancer 5 2019-01-07
Modified autologous leukocyte cells for the treatment of acute kidney injury after cardiac surgery Ended

2023-504610-30-01 Acute kidney injury after cardiac surgery 4 2026-04-29
Study with Enzalutamide to understand molecular alterations in prostate cancer Ended

2024-514786-19-01 PROSTATE CANCER 6 2025-01-27
Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed P… Ended

2024-518171-59-00 Prostate Cancer 11 2025-01-23
An open label, single-arm, phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patien… Ended

2023-504420-26-00 Bladder Cancer 4 2025-01-13
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer Ended

2024-511038-11-00 advanced prostate cancer 4 2024-09-24
A phase II, randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) w… Ended

2024-512023-37-00 Prostate cancer 4 2024-06-27
StayDry Ended

2023-510280-35-00 Daytime urinary incontinence 6 2024-05-27
A trial to examine the biological effects of Saruparib (AZD5305) alone, Darolutamide alone, and in combination in patients with newly diagno… Ended

2023-503691-25-00 Newly diagnosed prostate cancer 3 2023-12-11
A Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients with Primary IgA Nephr… Ended

2022-502102-32-00 Primary Immunoglobulin A (IgA) Nephropathy 5 2023-11-16
A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD… Ended

2022-501343-33-00 Biochemically recurrent prostate cancer 5 2023-10-18
Neoadjuvant ADT with TULSA Ended

2022-502067-38-00 Intermediate-risk prostate cancer 3 2023-06-29
A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 versus 2-weekly Docetaxel 50 mg/m2 in combination with Darolutamide + ADT … Ended

2022-502634-52-00 prostate cancer 5 2023-05-16
A Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resist… Ended

2022-501139-17-01 Aggressive Variant Metastatic Castration Resistant Pros 4 2023-05-05
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of [177Lu]LU-PSMA-I&T versus Hormone Therapy in Patie… Ended

2022-501493-19-00 metastatic Castration-Resistant Prostate Cancer (mCRPC) 5 2023-02-20
Radiotherapy in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to… Ended

2024-513633-20-00 recurrent prostate cancer 4 2022-10-28
A phase 2 study to investigate the effectiveness of combination immunotherapy followed by chemoradiation of the tumor in patients with bladd… Ended

2024-512211-41-00 Urothelial carcinoma of the bladder and bladder cancer 9 2022-01-26
Prospective, randomized, neoadjuvant phase II study with combination immuno-oncology in primary clear cell renal cell cancer at risk for rec… Ended

2024-515514-40-00 Resectable intermediate to high-risk clear cell RCC (ac 4 2022-01-05
NORTH-REG Dwell-Time Study Ended

2023-505936-37-00 Urothelial cancer 6 2021-02-03
Treatment Of Metastatic Bladder cancer at the time Of biochemical reLApse following radical cystectomy - TOMBOLA Ended

2024-510865-41-00 Urothelial cancer 6 2019-09-26